Search companies

Live

RECCE PHARMACEUTICALS LTD (ASX: RCE)

Health care · News and insights

Price unavailable

Latest RCE announcements

Announcement Insights

Recce Moves RECCE 327 Gel Into Phase 3 as Funding and Commercial Deals Advance

Recce reported patient dosing in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia at its November 6 AGM, building on October ethics approval for an amended Australian Phase 3 study. The company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet; funding included A$6.4 million raised through a placement and share purchase plan, alongside expected R&D tax rebate support.

Updated 16 Nov 2026, 05:43 PM Sydney time
Share
SourcesApplication for quotation of securities - RCECleansing NoticeAGM PresentationResults of MeetingOptions ProspectusRetirement of Mr Alistair McKeough as Non-Executive DirectorQuarterly Activities/Appendix 4C Cash Flow ReportApplication for quotation of securities - RCECleansing Notice
Comments

Recce Shareholders Reject Remuneration Report In Second Strike, But Block Board Spill

2026-11-06 · Health care

RCE: $0.330 +0.00% · MC: $113M

Recce Pharmaceuticals shareholders delivered a second strike against the remuneration report, with more than a quarter of votes cast opposing it, but rejected the spill resolution. The AGM presentation said patient dosing is underway in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia, with an independent committee expected to review Indonesian trial data as soon as mid-November; the company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet.

Updated 2026-11-06 13:32
Share
SourcesAGM PresentationResults of Meeting
Comments

Recce Director to Retire as Options Offers Open

2026-11-04 · Health care

RCE: $0.335 +0.00% · MC: $113M

Recce Pharmaceuticals director Alistair McKeough will retire after the November 6 AGM and will not seek re-election; the company has withdrawn the related resolution, and Alan Dunton will take over as Audit and Risk Committee chair. A prospectus also opens offers of unlisted options linked to the earlier placement, including up to 10 million additional options if attaching options are exercised.

Updated 2026-11-04 18:55
Share
SourcesOptions ProspectusRetirement of Mr Alistair McKeough as Non-Executive Director
Comments

Recce Advances Phase 3 Trial Plans as Cash Rebate Support Looms

2026-10-30 · Health care

RCE: $0.360 +9.09% · MC: $113M

Recce Pharmaceuticals says ethics approval is in place for an amended Australian Phase 3 study of its topical treatment for diabetic foot infections, while a Vietnamese patent expands its anti-infective intellectual property coverage. The company ended the quarter with about A$1 million in cash and expects an approximately A$7.5 million R&D tax rebate; it also reported receiving a further A$3.6 million rebate, bringing FY2025 rebates to approximately A$8.9 million. A completed share purchase plan and placement raised A$6.4 million in total, and the company issued shares under its employee incentive scheme.

Updated 2026-10-30 17:46
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow ReportApplication for quotation of securities - RCECleansing Notice
Comments